Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.7.3465

GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population  

Li, Hui-Yan (Department of Radiology, the Third Affiliated Hospital of Harbin Medical University)
Ge, Xin (Department of General Surgery, Heilongjiang Province's Hospital)
Huang, Guang-Ming (Department of General Surgery, Heilongjiang Province's Hospital)
Li, Kai-Yu (Department of General Surgery, Heilongjiang Province's Hospital)
Zhao, Jing-Quan (Department of General Surgery, Heilongjiang Province's Hospital)
Yu, Xi-Miao (Department of General Surgery, Heilongjiang Province's Hospital)
Bi, Wen-Si (Department of General Surgery, Heilongjiang Province's Hospital)
Wang, Yu-Lin (Department of Hepatopancreatobiliary and Splenic Medicine, Affiliated Hospital of Medical College of Chinese People's Armed Police Force)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.7, 2012 , pp. 3465-3469 More about this Journal
Abstract
Aim: Platinum agents have shown to be effective in the treatment of colorectal cancer. We assessed whether single nucleotide polymorphisms (SNPs) in GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln might predict the overall survival in patients receiving oxaliplatin-based chemotherapy in a Chinese population. Methods: SNPs of GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln in 335 colorectal cancer patients were assessed using TaqMan nuclease assays. Results: At the time of final analysis on Nov. 2011, the median follow-up period was 37.7 months (range from 1 to 60 months). A total of 229 patients died during follow-up. Our study showed GSTP1 Val/Val (HR=0.44, 95% CI=0.18-0.98), ERCC1 C/C (HR=0.20, 95% CI=0.10-0.79) and ERCC2 G/G (HR=0.48, 95% CI=0.19-0.97) to be significantly associated with better survival of colorectal cancer. GSTP1 Val/Val, ERCC1 C/C and ERCC2 G/G were also related to longer survival among patients with colon cancer, with HRs (95% CIs) of 0.41 (0.16-0.91), 0.16 (0.09-0.74) and 0.34 (0.16-0.91), respectively. Conclusion: GSTP1, GSTP1, ERCC1 Asn118Asn and ERCC2 Lys751Gln genotyping might facilitate tailored oxaliplatin-based chemotherapy for colorectal cancer patients.
Keywords
GSTP1; ERCC1 Asn118Asn; ERCC2 Lys751Gln; colorectal cancer; chemotherapy;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Baek SK, Kim SY, Lee JJ, et al (2006). Increased ERCC expression correlates with improved outcome of patients treated with cisplatin as an adjuvant therapy for curatively resected gastric cancer. Cancer Res Treat, 38, 19-24.   과학기술학회마을   DOI
2 Cao C, Zhang YM, Wang R, et al (2011). Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis. Chin Med J (Engl), 124, 2203-8.
3 Faivre S, Chan D, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37.   DOI
4 Han X, Xing Q, Li Y, et al (2012). Study on the DNA Repair Gene XRCC1 and XRCC3 Polymorphism in Prediction and Prognosis of Hepatocellular Carcinoma risk. Hepatogastroenterology, 59, doi: 10.5754/hge12096. [Epub ahead of print]
5 International Agency for Research on Cancer (2008). Colorectal Cancer Incidence and Mortality Worldwide in 2008. 2011, http://globocan.iarc.fr.
6 Ishibashi K, Okada N, Tajima Y, et al (2011). Prediction of the efficacy of modified FOLFOX6 therapy according to the mRNA levels of thymidylate synthase (TS), excision repair cross-complementing-1 and -2 ( ERCC-1 and ERCC-2) and methylenetetrahydrofolate dehydrogenase (MTHFD) in the primary lesion of colorectal cancer. Gan To Kagaku Ryoho, 38, 2220-3.
7 Jun L, Haiping Z, Beibei Y (2009). Genetic polymorphisms of GSTP1 related to response to 5-FU-oxaliplatin-based chemotherapy and clinical outcome in advanced colorectal cancer patients. Swiss Med Wkly, 139, 724-8.
8 Keam B, Im SA, Han SW, et al (2008). Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer, 8, 148.   DOI
9 Kim KH, Kwon HC, Oh SY, et al (2011). Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers, 16, 74-82.   DOI
10 Kweekel DM, Gelderblom H, Antonini NF, et al (2009). Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients. Eur J Cancer, 45, 572-8.   DOI
11 Leichman LP, Goldman BH, Bohanes PO, et al. S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. J Clin Oncol, 29, 4555-60.
12 Kweekel DM, Gelderblom H, Guchelaar HJ (2005). Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev, 31, 90-105.   DOI
13 Kwee S, Song MA, Cheng I, et al (2012). Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer. Clin Transl Sci, 5, 65-70.   DOI
14 Lascorz J, Bevier M, Schonfels WV, et al (2012). Polymorphisms in the mitochondrial oxidative phosphorylation chain genes as prognostic markers for colorectal cancer. BMC Med Genet, 13, 31.
15 Martin LP, Hamilton TC, Schilder RJ (2008). Platinum resistance: the role of DNA repair pathways. Clin Cancer Res, 14, 1291-5.   DOI   ScienceOn
16 Noda E, Maeda K, Inoue T, et al (2012). Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology, 59, 130-3.
17 Rajaraman P, Bhatti P, Doody MM, et al (2008). Nucleotide excision repair polymorphisms may modify ionizing radiation-related breast cancer risk in US radiologic technologists. Int J Cancer, 123, 2713-6.   DOI   ScienceOn
18 Reed E (2005). ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res, 11, 6100-2.   DOI
19 Rouissi K, Bahria IB, Bougatef K, et al (2011). The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer, 11, 101.   DOI
20 Sato K (1989). Glutathione S-transferases as markers of preneoplasia and neoplasia. Adv Cancer Res, 52, 205-55.   DOI
21 Sharma RA, Dianov GL (2007). Targeting base excision repair to improve cancer therapies. Mol Aspects Med, 28, 345-74.   DOI
22 Stoehlmacher J, Park DJ, Zhang W, et al (2002). Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst, 94, 936-42.   DOI
23 Stoehlmacher J, Park DJ, Zhang W, et al (2004). A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU ⁄ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer, 91, 344-54.
24 Storm HH, Engholm G, Hakulinen T, et al (2010). Survival of patients diagnosed with cancer in the Nordic countries up to 1999-2003 followed to the end of 2006. A critical overview of the results. Acta Oncol, 49, 532-44.   DOI
25 Sun JM, Ahn MJ, Park MJ, et al (2011). Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys, 80, 655-60.   DOI
26 Townsend DM, Tew KD (2003). The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene, 22, 7369-75.   DOI   ScienceOn
27 Woolston CM, Zhang L, Storr SJ, et al (2012). The prognostic and predictive power of redox protein expression for anthracycline-based chemotherapy response in locally advanced breast cancer. Mod Pathol, Apr 6.
28 Zhao Y, Deng X, Wang Z, et al (2012). Genetic Polymorphisms of DNA Repair Genes XRCC1 and XRCC3 and Risk of Colorectal Cancer in Chinese Population. Asian Pac J Cancer Prev, 13, 665-9.   과학기술학회마을   DOI   ScienceOn
29 Zha Y, Cun Y, Zhang Q, et al (2012). Prognostic Value of Expression of Kit67, p53, TopoIIa and GSTP1 for Curatively Resected Advanced Gastric Cancer Patients Receiving Adjuvant Paclitaxel plus Capecitabine Chemotherapy. Hepatogastroenterology, 59, 1327-32.